StreetAlpha.app
Home › Stocks › BVS

Bioventus Inc. (BVS)

Healthcare
$10.60
▲ +1.34%
LAST CLOSE · NOV 17

Bioventus makes pain treatment and surgical products for musculoskeletal care, sold to physicians, surgeons and hospitals. It last closed at $10.60 on Nov 17, up 1.34% on the day. In the past 30 days there were 1 dark pool print totaling $276K, the largest $276K.

AI Auto Pilots
Is BVS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$585.6M
+3.9% vs a year ago
Net income
$57.3M
+655.0% vs a year ago
EPS (diluted)
$0.81
+575.0% vs a year ago
Free cash flow
$85.0M
14.5% margin
Balance sheet
Cash & equivalents
$30.7M
At Sep 26
Debt
$229.8M
At Sep 26
Shareholder equity
$240.5M
Employees960 (Sep 26, 2026)
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $430.9M$430.9MFY2021FY2022: $512.1M$512.1MFY2022FY2023: $512.3M$512.3MFY2023FY2024: $573.3M$573.3MFY2024FY2025: $568.1M$568.1MFY2025

From BVS's SEC filings, latest 10-Q for the period ending Sep 26, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated BVS in the past 90 days, not enough for a consensus
Average 12-month target
$18.00
▲ 69.8% upside

Based on 1 analyst who set a price target on BVS in the past 90 days. The average target is $18.00, with a high of $18.00 and a low of $18.00, compared with the last close of $10.60.

Low $18.00Avg $18.00High $18.00
Blue marker: last close $10.60
Highest target$18.00
Average target$18.00
Lowest target$18.00
Latest rating changes
Canaccord GenuityTarget lowered
Nov 3Buy$19 → $18
Canaccord GenuityTarget raised
Aug 17Buy$15 → $19
Cantor FitzgeraldReiterated
Aug 17Buy$15
Barrington ResearchMaintained
Jun 30Buy$14
Canaccord GenuityMaintained
Jun 16Buy$15
DateFirmActionRatingPrice target
Nov 3Canaccord GenuityTarget loweredBuy$19 → $18
Aug 17Canaccord GenuityTarget raisedBuy$15 → $19
Aug 17Cantor FitzgeraldReiteratedBuy$15
Jun 30Barrington ResearchMaintainedBuy$14
Jun 16Canaccord GenuityMaintainedBuy$15
Loading…

Technical Analysis

BVS · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, nearing oversold

The stock is 17% below its 20 day and 23% below its 50 day average. It is 5% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the Pivot at $10.48, and the nearest resistance the Pivot R1 at $10.75.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 5.9%/day
Key levels
$15.8952 week high+49.9%
$13.0050 day average+22.6%
$12.98100 day average+22.5%
$12.4420 day average+17.4%
$11.09200 day average+4.6%
$11.00Swing high (May 20)+3.8%
$10.75Pivot R1+1.4%
$10.60Last close
$10.48Pivot−1.1%
$10.32Pivot S1−2.6%
$10.09Swing low (Nov 3)−4.8%
$6.4752 week low−39.0%
Indicators
RSI (14)33.50Weak, oversold below 30Neutral
MACD-0.84Below its signal lineBearish
Stochastic9.7Near the bottom of its rangeOversold
ADX (14)30.1Trending down
Williams %R-89.8Oversold below −80, overbought above −20Oversold
CCI (20)-75.5Oversold below −100, overbought above 100Neutral
Rate of change−3.1%Change over 10 sessionsBearish
ATR (14)$0.62Typical daily range, 5.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BVS

What happened before

See how BVS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow BVS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How BVS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in BVS in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$276K
Largest print
$276K
Loading…

BVS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲92 buying vs 75 selling
  • ▼Shares held by funds -4.2%
  • ▲Funds holding +13
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding170157+8.3%
In funds' top 10330.0%
Held by funds–––
New / increased35 / 5724 / 76−8.0%
Reduced / sold out50 / 2537 / 23+25.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BVS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BVS is in one of them and how their past BVS trades turned out.

BVS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BVS in an article yet. Here's the latest on the wider market.

About Bioventus

Bioventus is a medical device company based in Durham, North Carolina. It makes products that relieve pain and treat musculoskeletal conditions, including hyaluronic acid knee injections, implantable nerve stimulation systems for chronic pain, and ultrasonic bone cutting tools used in spine and neurosurgery. The company also offers bone graft substitutes that support bone fusion and a device that uses low intensity pulse ultrasound to help fractures heal. Its customers include physicians and surgeons, along with the hospitals, clinics and ambulatory surgical centers where patients are treated.

Headquarters
Durham, NC